AGENUS INC (AGEN)

US00847G7051 - Common Stock

0.6592  -0.01 (-1.38%)

Premarket: 0.7139 +0.05 (+8.3%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AGENUS INC

NASDAQ:AGEN (2/21/2024, 7:24:46 PM)

Premarket: 0.7139 +0.05 (+8.3%)

0.6592

-0.01 (-1.38%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap251.48M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AGEN Daily chart

Company Profile

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 533 full-time employees. The company went IPO on 2000-02-04. The firm is focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company’s I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company’s antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.

Company Info

AGENUS INC

3 Forbes Rd

Lexington MASSACHUSETTS 02421

P: 17816744400

CEO: Garo H. Armen

Employees: 533

Website: https://agenusbio.com/

AGEN News

News Image7 days ago - The Motley FoolWhy Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today

The company hopes to engineer a 1-for-20 reverse stock split.

News Image7 days ago - ChartmillWhich stocks are moving on Thursday?

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

News Image7 days ago - Seeking AlphaGinkgo stock gains after $31M contract win with Agenus

SaponiQx, a unit of Agenus (AGEN), and Ginkgo Bioworks (DNA) have won a multi-year contract worth up to $31M to sudy vaccine adjuvants. Read more here.

News Image7 days ago - ChartmillWhich stocks are moving on Thursday?

Top movers in Thursday's session

News Image7 days ago - Ginkgo BioworksGinkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

/PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program...

News Image14 days ago - Seeking AlphaModerna RSV vaccine lags rival shots in long-term efficacy

TD Cowen argues that Moderna's (MRNA) upcoming mRNA-based RSV vaccine has a faster decline in efficacy compared to rival shots from Pfizer (PFE) and GSK (GSK). Read more here.

AGEN Twits

Here you can normally see the latest stock twits on AGEN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example